Insulet Corp

PODD remains in a Stage 4 decline with both medium- and long-term biases bearish. Price is extended below falling EMAs and near the 52-week low, with RSI deeply oversold but no exhaustion visible. Short-term rallies into the 9/21 EMA zone offer optimal sell entries, warranting immediate participation in the breakdown.

• ↑Q2 revenue $802M, +23% YoY (constant currency).
• ↑Adjusted EPS rose 41.5% to $1.66.
• ↓Negative earnings yield and low book-to-price ratio imply overvaluation.